These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32183018)

  • 21. Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.
    Muenzer J; Ho C; Lau H; Dant M; Fuller M; Boulos N; Dickson P; Ellinwood NM; Jones SA; Zanelli E; O'Neill C
    Mol Genet Metab; 2024 Jul; 142(4):108535. PubMed ID: 39018614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.
    Zhang H; Young SP; Millington DS
    Curr Protoc Hum Genet; 2013; Chapter 17():Unit 17.12. PubMed ID: 23315926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan.
    Lin HY; Lee CL; Lo YT; Tu RY; Chang YH; Chang CY; Chiu PC; Chang TM; Tsai WH; Niu DM; Chuang CK; Lin SP
    Diagnostics (Basel); 2019 Oct; 9(4):. PubMed ID: 31590383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukocyte Imbalances in Mucopolysaccharidoses Patients.
    Lopes N; Maia ML; Pereira CS; Mondragão-Rodrigues I; Martins E; Ribeiro R; Gaspar A; Aguiar P; Garcia P; Cardoso MT; Rodrigues E; Leão-Teles E; Giugliani R; Coutinho MF; Alves S; Macedo MF
    Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
    Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
    Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
    Rowan DJ; Tomatsu S; Grubb JH; Montaño AM; Sly WS
    J Inherit Metab Dis; 2013 Mar; 36(2):235-46. PubMed ID: 22971960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry.
    Gold H; Mirzaian M; Dekker N; Joao Ferraz M; Lugtenburg J; Codée JD; van der Marel GA; Overkleeft HS; Linthorst GE; Groener JE; Aerts JM; Poorthuis BJ
    Clin Chem; 2013 Mar; 59(3):547-56. PubMed ID: 23237761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Separation of sulfated urinary glycosaminoglycans by high-resolution electrophoresis for isotyping of mucopolysaccharidoses in Malaysia.
    Nor A; Zabedah MY; Norsiah MD; Ngu LH; Suhaila AR
    Malays J Pathol; 2010 Jun; 32(1):35-42. PubMed ID: 20614724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses.
    Hochuli M; Wüthrich K; Steinmann B
    NMR Biomed; 2003 Jun; 16(4):224-36. PubMed ID: 14558120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine.
    Coppa GV; Gabrielli O; Zampini L; Maccari F; Mantovani V; Galeazzi T; Santoro L; Padella L; Marchesiello RL; Galeotti F; Volpi N
    Metab Brain Dis; 2015 Dec; 30(6):1343-8. PubMed ID: 26016623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Untargeted LC-HRMS metabolomics reveals candidate biomarkers for mucopolysaccharidoses.
    Torres CL; Scalco FB; de Oliveira MLC; Peake RWA; Garrett R
    Clin Chim Acta; 2023 Feb; 541():117250. PubMed ID: 36764508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry.
    Mashima R; Sakai E; Tanaka M; Kosuga M; Okuyama T
    Mol Genet Metab Rep; 2016 Jun; 7():87-91. PubMed ID: 27331006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucopolysaccharidosis III: Molecular basis and treatment.
    Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses.
    Tomatsu S; Okamura K; Maeda H; Taketani T; Castrillon SV; Gutierrez MA; Nishioka T; Fachel AA; Orii KO; Grubb JH; Cooper A; Thornley M; Wraith E; Barrera LA; Laybauer LS; Giugliani R; Schwartz IV; Frenking GS; Beck M; Kircher SG; Paschke E; Yamaguchi S; Ullrich K; Haskins M; Isogai K; Suzuki Y; Orii T; Kondo N; Creer M; Okuyama T; Tanaka A; Noguchi A
    J Inherit Metab Dis; 2005; 28(2):187-202. PubMed ID: 15877208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and molecular analysis of mucopolysaccharidoses in Turkey.
    Emre S; Terzioğlu M; Coşkun T; Tokath A; Ozalp I; Müller V; Hopwood J
    Turk J Pediatr; 2002; 44(1):13-7. PubMed ID: 11858372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucopolysaccharidoses and the eye.
    Ashworth JL; Biswas S; Wraith E; Lloyd IC
    Surv Ophthalmol; 2006; 51(1):1-17. PubMed ID: 16414358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Heparan Sulfate Proteoglycans as a Novel Therapeutic Strategy for Mucopolysaccharidoses.
    De Pasquale V; Sarogni P; Pistorio V; Cerulo G; Paladino S; Pavone LM
    Mol Ther Methods Clin Dev; 2018 Sep; 10():8-16. PubMed ID: 29942826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.